Gary Rabin's 25-year career in finance and operations has primarily encompassed investing in, managing and raising capital for small-cap and emerging growth companies. More >>
Dr. Robert Lanza joined ACT in 1999 and has over 30 years of research and industrial experience in the area of stem cells and regenerative medicine. He is currently an Adjunct Professor at the Institute for Regenerative Medicine at Wake Forest University School of Medicine, and has hundreds of publications, including over two dozen scientific and medical books. More >>
Edmund Mickunas brings 29 years of experience from a number of disciplines including biotechnology, medical devices and pharmaceuticals. He has worked in preclinical program development, clinical affairs, regulatory affairs/compliance and quality assurance and has worked closely with all disciplines involved in product development. Prior to joining ACT, Mr. Mickunas was Executive Director, Regulatory Affairs and Quality Assurance, for Applied Genetic Technologies Corporation, a privately held gene therapy and genomics-focused biotechnology company. Before that he was Senior Director of Regulatory Affairs and Compliance for Control Delivery Systems, Inc., where he managed the submissions of IND filings, among other responsibilities. Mr. Mickunas has also held senior regulatory positions at Bioheart, Inc., Cytomed and Del Laboratories. He received his B.S. and pursued graduate studies in human biochemistry at Fairleigh Dickinson University, and he holds a Masters Degree from Fairfield University.
For the past 29 years, Dr. Roger Gay has been involved in clinical manufacturing and product development at a number of biotechnology companies specializing in cell-based products and services, including Organogenesis, Diacrin, Genvec and Mytogen (which was later acquired by ACT). He has extensive experience directing and leading product development and clinical trial manufacturing for cellular products, having planned and executed R&D programs leading to market introduction of first-ever products for two biotechnology companies prior to joining ACT. Dr. Gay holds a Ph.D. in biochemistry from the University of Rochester and was a post-doctoral fellow at Harvard Medical School.
Matt Vincent joined ACT in 2011 as Director of Corporate Development, having worked as outside intellectual property (IP) counsel and then as a business development consultant with the company since 2005. Dr. Vincent has 21 years of relevant experience in the life sciences industry, ranging from intellectual property strategy and patent litigation, to strategic partnering and collaborations, to regulatory affairs and clinical trial management. Dr. Vincent holds a B.S. in Chemistry from Worcester Polytechnic Institute, a Ph.D. in Biochemistry from Tufts University School of Medicine and a J.D. from Suffolk University School of Law. He holds several patents and has co-founded a number of life science companies, two of which have FDA-approved products or are currently in human clinical trials.
A native of Massachusetts, Rita Parker has a 20-year career in management. Prior to joining ACT Ms. Parker held senior positions in marketing and operational management focused on paving the way for local businesses to expand their geographical footprint and increasing their technological and productive capabilities by introducing new and efficient information technology products and systems. These companies include Digital Equipment Corporation, Computer Devices and Banyan Systems, Inc.
With over 15 years experience as an accountant, primarily in the manufacturing and insurance sectors, Kathy Singh brings an extensive skill set and insight to her position. Ms. Singh received both her undergraduate degree in Business and MBA from the University of Memphis.